AbbVie v. Prinston Pharmaceutical: Elagolix Patent Case Consolidated in Delaware
AbbVie filed suit in the District of Delaware against Prinston Pharmaceutical, Solco Healthcare US, and Zhejiang Huahai Pharmaceutical, asserting two patents covering methods of administering elagolix. After 419 days, the case was folded into a broader consolidated action involving seven related proceedings before Judge Jennifer L. Hall.
Seven-case elagolix patent wave consolidated in Delaware District Court
AbbVie, Inc. filed this infringement action on 28 April 2023 in the District of Delaware against Prinston Pharmaceutical, Inc., Solco Healthcare US, LLC, and their Chinese parent Zhejiang Huahai Pharmaceutical Co., Ltd. The suit asserted US10682351B2 and US10537572B2, both directed to methods of administering elagolix — the active ingredient in AbbVie’s Orilissa and Oriahnn products indicated for endometriosis and uterine fibroids respectively. The defendants are generic pharmaceutical companies whose ANDA filings triggered the Hatch-Waxman litigation.
The case was not decided on its merits. Instead, on 20 June 2024, the parties stipulated and the court approved consolidation of this action with six other related cases — C.A. Nos. 22-1423, 23-374, 23-448, 23-607, 23-684, and 23-750 — into a single consolidated proceeding captioned under lead case C.A. No. 22-1423-RGA-JLH. All future filings, including any trial, now proceed on the consolidated docket. The Protective Order from the lead case governs all parties.
The 419-day arc from filing to consolidation is consistent with the standard pre-scheduling, claim construction briefing, and case management phase in Hatch-Waxman matters in Delaware. Consolidation of seven parallel ANDA cases suggests AbbVie is pursuing a coordinated enforcement strategy across multiple generic challengers simultaneously. The public record for this individual docket is silent on substantive merits disputes, claim construction positions, or settlement discussions — those will now surface only in the consolidated lead docket.
Filing to Case Consolidated in 419 days
419 days — typical for ANDA consolidation in D. Del. before merits phase
Case consolidated: what the merger into lead docket means for both parties
Consolidation merges seven ANDA cases into one proceeding
Under Fed. R. Civ. P. 42(a), courts may consolidate cases sharing common questions of law or fact. Here, seven related Hatch-Waxman actions asserting overlapping elagolix patents against different generic filers were merged into lead case C.A. No. 22-1423-RGA-JLH. This is a procedural step, not a merits ruling — all substantive disputes continue under the consolidated caption.
Procedural — no merits rulingAbbVie gains efficiency: one venue, one schedule, unified discovery
Consolidation benefits a plaintiff asserting the same patents against multiple defendants. AbbVie can now coordinate expert witnesses, claim construction arguments, and trial strategy across all seven generic challengers in a single proceeding. This reduces per-case litigation cost and lowers the risk of inconsistent rulings on the same patent claims.
Plaintiff-favoured procedural postureGeneric defendants face coordinated opposition in consolidated docket
Prinston, Solco, and Zhejiang Huahai must now litigate alongside other ANDA filers in a single proceeding, which can limit independent litigation strategies. However, consolidation also allows defendant-side coordination on invalidity and non-infringement positions, potentially sharing the burden of prior art searches and expert costs.
Mixed impact for generic defendantsElagolix market entry for generics remains contingent on lead case outcome
Until the consolidated action resolves, the 30-month stay under Hatch-Waxman typically blocks FDA approval of the generic ANDAs. The breadth of the consolidation — seven cases — signals that the elagolix patent estate is being actively defended across the entire generic pipeline. Market entry timing for all challengers is now tied to a single consolidated litigation outcome.
Generic market entry at riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Pharmaceutical innovator — holder of US10682351B2 and US10537572B2 (elagolix)Search in Eureka ↗ |
| Defendant | Prinston Pharmaceutical, Inc. | Company | Generic pharma group: Prinston Pharmaceutical, Solco Healthcare US, and Zhejiang Huahai PharmaceuticalSearch in Eureka ↗ |
| Co-Defendant | Solco Healthcare US, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Zhejiang Huahai Pharmaceutical Co., Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel Taylor | Attorney | Counsel for Prinston Pharmaceutical, Inc.Search in Eureka ↗ |
| Defendant law firm | Smith, Katzenstein & Jenkins LLP | Law Firm | Representing Prinston Pharmaceutical, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order in this case is purely procedural — it does not adjudicate infringement, validity, or any substantive patent claim. The language reflects a mutually agreed administrative consolidation, merging this docket into the lead case to streamline seven parallel Hatch-Waxman proceedings. Neither party conceded any legal position. All merits analysis must be tracked through the consolidated lead docket C.A. No. 22-1423-RGA-JLH.
US10682351B2 & US10537572B2 — Methods of administering elagolix
US10682351B2 (application no. US16/722741) and US10537572B2 (application no. US15/957469) both protect methods of administering elagolix, a GnRH receptor antagonist approved for treating endometriosis-associated pain and heavy menstrual bleeding from uterine fibroids. Method-of-treatment claims of this type define how the drug is dosed and administered, rather than the compound itself, and can remain enforceable even after a core compound patent expires.
For AbbVie, these patents underpin the Hatch-Waxman exclusivity strategy for Orilissa and Oriahnn, two commercially significant women’s health products. Method patents are strategically valuable because generic ANDA filers cannot easily design around dosing regimens that are central to labelling. Any generic label that mirrors the branded dosing instructions risks inducing infringement, making these patents a durable barrier to generic entry and a focal point for any freedom-to-operate assessment in this space.
Should you run an FTO against US10682351B2 and US10537572B2?
Any company developing, filing an ANDA for, or commercialising elagolix-based products — or GnRH receptor antagonists with overlapping administration methods — should conduct a formal freedom-to-operate analysis against these patents. The method-of-treatment claim scope means that even a non-infringing formulation may create inducement liability if the product label directs patients to use the drug in ways covered by these claims.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US10682351B2 and US10537572B2 against your product’s proposed labelling and dosing regimen, surface the relevant prosecution history, and identify prior art that may support invalidity arguments. Use Eureka to monitor the consolidated lead docket for claim construction orders that could redefine the enforceable scope of these method claims before your ANDA filing.
Run a freedom-to-operate analysis on US10682351B2 to assess your product’s exposure
Run FTO in Eureka →Similar elagolix and GnRH antagonist ANDA patent cases in Delaware
Explore related Hatch-Waxman method patent cases involving GnRH receptor antagonists and women’s health drugs litigated in the District of Delaware.
What this case signals for the elagolix and women’s health IP landscape
AbbVie’s seven-case enforcement wave against elagolix generics illustrates the Hatch-Waxman litigation playbook for blockbuster specialty pharma assets.
Multi-defendant ANDA consolidation is now standard Delaware practice
Delaware courts routinely consolidate parallel ANDA cases involving the same drug and overlapping patents. IP teams monitoring branded pharmaceutical portfolios should track lead docket numbers — individual case closures via consolidation do not signal resolution of the underlying patent dispute.
Elagolix method patents extend exclusivity beyond the compound itself
US10682351B2 and US10537572B2 claim methods of administration, not just the molecule. Method-of-treatment patents are harder to design around and can sustain Hatch-Waxman litigation even after compound exclusivity expires. Generic entrants must assess both formulation and method claims before ANDA filing.
AbbVie v Prinston — key questions answered
The case was closed on 20 June 2024 via consolidation into lead case C.A. No. 22-1423-RGA-JLH in the District of Delaware. No merits ruling was issued. The court merged seven parallel Hatch-Waxman cases involving elagolix patents into a single consolidated proceeding, where all future litigation will be conducted.
AbbVie asserted US10682351B2 and US10537572B2. Both patents cover methods of administering elagolix, a GnRH receptor antagonist used in Orilissa and Oriahnn for endometriosis and uterine fibroids. These are method-of-treatment patents rather than compound patents.
The case was one of seven related Hatch-Waxman actions asserting overlapping elagolix patents against different generic filers. Consolidation under Fed. R. Civ. P. 42(a) merged all seven into lead case C.A. No. 22-1423-RGA-JLH. The underlying patent dispute continues — consolidation is a procedural step, not a resolution on the merits.
The defendants in Case No. 1:23-cv-00470 are Prinston Pharmaceutical, Inc., Solco Healthcare US, LLC, and Zhejiang Huahai Pharmaceutical Co., Ltd. Zhejiang Huahai is a major Chinese pharmaceutical manufacturer and the parent of Prinston and Solco, suggesting the ANDA supply chain has offshore origins.
Method-of-treatment patents claim how a drug is administered rather than the drug compound itself. In Hatch-Waxman cases, these patents are significant because a generic label that mirrors branded dosing instructions can constitute induced infringement even if the formulation itself is non-infringing. They typically extend the effective exclusivity period beyond compound patent expiry.
PatSnap Eureka searches patents and litigation data to answer instantly.